Quark Biotech, Inc.

Quark Biotech a privately held U.S. company, is pioneering Endpoint Driven Drug Development (ED3) to efficiently develop superior therapeutics to treat complex diseases. ED3 is a vertically integrated drug development approach that starts with defining a desired clinical endpoint in any specified disease, to identify drug candidates that achieve the desired endpoint. The Company is currently focused on therapeutics to treat metabolic disorders and their co-morbodities.

Quark has several promising drug candidates addressing metabolic disorders, cancer, fibrotic, and ischemic diseases. Quark’s lead drug, QC-BT16 is targeted for the market of dyslipidemia, and for the “Metabolic Syndrome” market. Metabolic syndrome is a complex disorder composed of obesity, dyslipidemia, insulin-resistance (diabetes mellitus type II) and hypertension – affecting approximately 25% of the American adult population. QC-BT16 has an open IND, has completed Phase I human safety and pharmacokinetics studies as well as several pilot phase IIa studies and is currently entering full-scale Phase II trials.

Careers at Quark Click here

Human Resources
Employment opportunities
Smadar Manor
E-Mail: manor@qbi.co.il
 

Corporate Headquarters:
USA - Quark Biotech, Inc.
6536 Kaiser Drive
Fremont, CA 94555, USA
Phone: (510) 402-4020
Fax: (510) 402-4021

Israel
QBI Enterprises, Ltd.
Weizmann Science Park,P.O.B. 4071
Ness Ziona, 70400, Israel
Phone: 972-8-9305-111
Fax: 972-8-9406-476
E-Mail: qbi@qbi.co.il


Japan
Operations Japan & Far East
Tatsuo Arita,Ph.D.
Osaka, Japan
Phone: 81-6-6532-5301
Fax: 81-6-6352-5329
E-Mail: cycloped@aol.com